PMDA drug package insert
マヴィレット配合顆粒小児用
PMDA Prescription drug · アッヴィ合同会社 · package insert Aug 1, 2023
Key facts
| Brand names | マヴィレット配合顆粒小児用 |
|---|---|
| Nonproprietary names | グレカプレビル水和物・ピブレンタスビル |
| Companies | 製造販売元／アッヴィ合同会社 |
| Product type | Prescription drug |
| Therapeutic category | 抗ウイルス化学療法剤 |
| Therapeutic category codes | 87625 |
| YJ codes | 6250113D1020 |
| Approval numbers | 30400AMX00206000 |
| Package insert edition | 第2版 |
| Package insert date | Aug 1, 2023 |
| PMDA document key | 112130_6250113D1020_1 |
| PMDA company code | 112130 |
At a glance
- 1–9 Package insert revisions
- 1–9 Related PMDA documents
- None Safety communications
- Yes PMDA review report published
- Yes Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: